Volume 12, Number 8—August 2006
Research
Antibody Response to Pneumocystis jirovecii
Kieran R. Daly*†, Laurence Huang‡, Alison Morris§, Judy Koch*†, Kristina Crothers‡¶, Linda Levin†, Shary Eiser‡, Supriya Satwah†, Patrizia Zucchi‡#, and Peter D. Walzer*†
Table 4
Antibody levels to major surface glycoprotein A in Pneumocystis pneumonia (PCP) patients by history of PCP and week of observation*
| Week | Combined |
No history of PCP |
History of PCP |
|||
|---|---|---|---|---|---|---|
| n | Geometric mean (95% CI) | n | Geometric mean (95% CI) | n | Geometric mean (95% CI) | |
| Baseline (0) | 78 | 5.6 (3.9–7.9) | 59 | 5.8 (3.9–8.7) | 19 | 4.7 (2.1–10.5) |
| 1–2 | 24 | 12.0 (6.7–21.4) | 18 | 13.7 (7.0–26.8) | 6 | 7.6 (1.2–47.4) |
| 3–4 | 17 | 11.5 (5.2–25.3) | 11 | 13.7 (4.3–43.5) | 6 | 7.3 (1.1–48.9) |
| 5–6 | 17 | 5.1 (2.3–11.3) | 13 | 4.0 (1.9–8.2) | 4 | 5.7 (0.2–207.9) |
*n = no. patients who were observed at the specified follow-up time and at baseline. CI, confidence interval.
